Cargando…
Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313866/ https://www.ncbi.nlm.nih.gov/pubmed/34396130 http://dx.doi.org/10.1136/bmjno-2020-000096corr1 |
Ejemplares similares
-
Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
por: Karunaratne, Kushan, et al.
Publicado: (2021) -
Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016) -
Overlapping anti-NMDAR encephalitis and multiple sclerosis: A case report and literature review
por: Liu, Pan, et al.
Publicado: (2023) -
Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
por: Lin, Yen Chih, et al.
Publicado: (2015) -
Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
por: Reardon, Jennifer, et al.
Publicado: (2013)